Lewis T, J Cook: Fluoroquinolones and tendinopathy: a guide for athletes and sports clinicians and a systematic review of the literature. J Athl Train 49: 422, 2014.
Ansari S Y Yamaoka: Current understanding and management of Helicobacter pylori infection: an updated appraisal. F1000Res 7, 2018.
Tam PK, CT Ho: Fluoroquinolone-induced Achilles tendinitis. Hong Kong Med J 20: 545, 2014.
Melhus A, et al: Levofloxacin-associated Achilles tendon rupture and tendinopathy. Scand J Infect Dis 35: 768, 2003.
Aydin S, et al: A rare case of spontaneous, bilateral Achilles tendon rupture in systemic lupus erythematosus and a review of the literature. Lupus 17: 1051, 2008.
Lado Lado FL, et al: Partial bilateral rupture of the Achilles tendon associated to levofloxacin. An Med Interna 22: 28, 2005.
Haddow LJ, et al: Spontaneous Achilles tendon rupture in patients treated with levofloxacin. J Antimicrob Chemother 51: 747, 2003.
Tanne JH: FDA adds “black box” warning label to fluoroquinolone antibiotics. BMJ 337: a816, 2008.
Emergency Medicines Agency: Fluoroquinolone antibiotics: reminder of measures to reduce the risk of long-lasting, disabling and potentially irreversible side effects. European Medicines Agency. [Online] May 12, 2023. Available at: https://www.ema.europa.eu/en/news/fluoroquinolone-antibiotics-reminder-measures-reduce-risk-long-lasting-disabling-and-potentially-irreversible-side-effects. Accessed October 1, 2023.
Connelly S, C Bayliff, S Mehta: Levofloxacin-induced bilateral Achilles tendinopathy. Can J Hosp Pharm 55: 212, 2002.
This case report aims to demonstrate a rare occurrence of tendon rupture attributable to levofloxacin use in Helicobacter pylori eradication. On the seventh day of treatment, the patient experienced severe foot pain and difficulty in walking, leading to a diagnosis of Achilles tendon rupture confirmed through magnetic resonance imaging. Levofloxacin-induced tendinopathy and/or rupture are rare complications that are often linked to age and sex. Health-care providers should exercise caution when prescribing fluoroquinolones, especially to at-risk patients, and should inform them about potential side effects.